» Articles » PMID: 15540201

Aberrant Expression of Serine/threonine Kinase Pim-3 in Hepatocellular Carcinoma Development and Its Role in the Proliferation of Human Hepatoma Cell Lines

Overview
Journal Int J Cancer
Specialty Oncology
Date 2004 Nov 13
PMID 15540201
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Most cases of human hepatocellular carcinoma develop after persistent chronic infection with human hepatitis B virus or hepatitis C virus, and host responses are presumed to have major roles in this process. To recapitulate this process, we have developed the mouse model of hepatocellular carcinoma using hepatitis B virus surface antigen transgenic mice. To identify the genes associated with hepatocarcinogenesis in this model, we compared the gene expression patterns between pre-malignant lesions surrounded by hepatocellular carcinoma tissues and control liver tissues by using a fluorescent differential display analysis. Among the genes that were expressed differentially in the pre-malignant lesions, we focused on Pim-3, a member of a proto-oncogene Pim family, because its contribution to hepatocarcinogenesis remains unknown. Moreover, the unavailability of the nucleotide sequence of full-length human Pim-3 cDNA prompted us to clone it from the cDNA library constructed from a human hepatoma cell line, HepG2. The obtained 2,392 bp human Pim-3 cDNA encodes a predicted open reading frame consisting of 326 amino acids. Pim-3 mRNA was selectively expressed in human hepatoma cell lines, but not in normal liver tissues. Moreover, Pim-3 protein was detected in human hepatocellular carcinoma tissues and cell lines but not in normal hepatocytes. Furthermore, cell proliferation was attenuated and apoptosis was enhanced in human hepatoma cell lines by the ablation of Pim-3 gene with RNA interference. These observations suggest that aberrantly expressed Pim-3 can cause autonomous cell proliferation or prevent apoptosis in hepatoma cell lines.

Citing Articles

PIM1 kinase and its diverse substrate in solid tumors.

Choudhury R, Bahadi C, Ray I, Dash P, Pattanaik I, Mishra S Cell Commun Signal. 2024; 22(1):529.

PMID: 39487435 PMC: 11531143. DOI: 10.1186/s12964-024-01898-y.


PIM Kinase Inhibitors as Novel Promising Therapeutic Scaffolds in Cancer Therapy.

Karati D, Saha A, Roy S, Mukherjee S Curr Top Med Chem. 2024; 24(28):2489-2508.

PMID: 39297470 DOI: 10.2174/0115680266321659240906114742.


Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease.

Meur S, Mukherjee S, Roy S, Karati D Mol Neurobiol. 2024; 61(12):10941-10955.

PMID: 38816674 DOI: 10.1007/s12035-024-04257-7.


PIM3 Kinase: A Promising Novel Target in Solid Cancers.

Atalay P, Ozpolat B Cancers (Basel). 2024; 16(3).

PMID: 38339286 PMC: 10854964. DOI: 10.3390/cancers16030535.


An overview of pim kinase as a target in multiple myeloma.

Liu Z, Zhang Y, Guo Y, Wang H, Fu R Cancer Med. 2023; 12(10):11746-11759.

PMID: 37162273 PMC: 10242321. DOI: 10.1002/cam4.5797.